A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
This is a multiple-center, multiple-dose, randomized, active comparator-controlled,
double-masked, three parallel group, 36-week study in participants with center-involving
diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes
meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA)
will be defined as the study eye. The study will consist of a treatment period (20 weeks) and
an observational period (up to 16 weeks). Treatment naive participants will be randomized in
a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated
with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in
a 1:1 ratio to Arms A and C.